Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 16/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 16/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.46 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20849918 | 0.86 | CCNK (0.45) | CCNKCDK12AURKAAURKBINCENP | |
| SCHEMBL20839652 | 0.84 | CCNK (0.69) | CCNKCDK12NUDT1 | |
| SCHEMBL20839682 | 0.81 | CCNK (0.67) | CCNKCDK12AURKAAURKBINCENP | |
| SCHEMBL20840000 | 0.77 | CCNK (0.44) | CCNKCDK12NUDT1 | |
| SCHEMBL20839755 | 0.75 | CCNK (0.63) | CCNKCDK12 | |
| SCHEMBL22305138 | 0.72 | CCNK (0.60) | CCNKCDK12NUDT1 | |
| SCHEMBL20839836 | 0.72 | CCNK (0.40) | CCNKCDK12NUDT1 | |
| SCHEMBL20839690 | 0.70 | CCNK (0.69) | CCNKCDK12 | |
| SCHEMBL22285857 | 0.67 | DAO (0.38) | CCNKCDK12 | |
| SCHEMBL3413368 | 0.66 | IKBKB (0.80) | AURKBROCK1IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684776-B1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | UNIV NOTTINGHAM (GB) | 2023-11-01 | — | — | EP | disclosed |
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2020-08-06 | — | — | US | disclosed |
| EP-3684776-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | The University of Nottingham (GB) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019058132-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | CDK1, CDK11A, CDK12 | CCNK 18/4885CDK12 3/4885AURKA 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.